ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 864

Anticytokine Autoantibody Profiling in Five Types of Systemic Vasculitis

Sarthak Gupta1,2, Seema K. Patel2, Mary Blake2, Massimo G. Gadina2, Wanxia L. Tsai2, Simon Carette3, David Cuthbertson4, Gary S. Hoffman5, Nader A. Khalidi6, Curry L. Koening7, Carol A. Langford5, Carol A. McAlear8, Larry W. Moreland9, Paul A. Monach10, Christian Pagnoux3, Philip Seo11, Ulrich Specks12, Antoine G. Sreih13, Steven R. Ytterberg14, Sarah K. Browne1,15, Steven M. Holland1, Mariana J. Kaplan2, Peter A. Merkel16, Peter C. Grayson2 and Vasculitis Clinical Research Consortium, 1Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 2National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 3Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, 4Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, 5Rheumatology, Cleveland Clinic, Cleveland, OH, 6Division of Rheumatology, St. Joseph’s Health Care, McMaster University, Hamilton, ON, Canada, 7Division of Rheumatology, University of Utah, Salt Lake City, UT, 8Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, 9Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 10Rheumatology, Boston University School of Medicine, Boston, MA, 11Division of Rheumatology, Johns Hopkins University, Baltimore, MD, 12Division of Pulmonary and Critical Care Medicine, Mayo Clinic College of Medicine, Rochester, MN, 13Department of Rheumatology, University of Pennsylvania, Philadelphia, PA, 14Rheumatology Division, Mayo Clinic, Rochester, MN, 15Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, 16Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: autoantibodies, large vessel vasculitis, polyarteritis nodosa and vasculitis, Wegener's granulomatosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Vasculitis Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

Anticytokine autoantibodies (ACAs) are pathogenic in many
hematologic, pulmonary and infectious diseases. Evaluation in autoimmune
diseases, including systemic
lupus erythematosus (SLE), shows that ACAs are biologically active and may
contribute to disease pathogenesis. The
prevalence of ACAs and their correlation to
circulating cytokine levels in vasculitis
has not been characterized and was the focus of this study.

Methods:

Patients with various forms of vasculitis were selected from a
multicentered, observational cohort and fulfilled modified ACR classification criteria for the respective
diseases. All patients had active disease at the time of sample collection and
had not received cyclophosphamide or rituximab within 6 months prior to sample
collection. Plasma samples from patients with 5
types of vasculitis (n=149) and healthy controls (n=25) were tested for autoantibodies
against 34 cytokines using a multiplex bead-based assay. For each ACA concentrations
above two standard deviations of the mean of healthy controls and more than
1000 fluorescence intensity were classified as positive. Cytokine measurements
were done using Human 25-Plex Panel (Invitrogen, Inc). Data were acquired on a Bio-Plex 100 instrument. Spearman’s
correlation coefficients were calculated to detect potential associations
between levels of cytokines and the relevant ACA.

Results:

The majority of patients (57%) had at least one ACA; however, the
prevalence of individual ACA ranged from 0 to 33% (Table 1). Autoantibodies
against TNF and LT
a were seen in the setting of anti-TNF
monoclonal therapy. Compared to other types of vasculitis, an increased
prevalence of autoantibodies against Th2
cytokines (IL-4, 5, 10, 13, up to 17%) were seen in Takayasu’s arteritis and
autoantibodies against G-CSF (15%) and IL-2 (23%) were detected in
granulomatosis with polyangiitis (GPA). No autoantibodies against IL-6 were
seen. Significant correlations were identified in 2 of 18 relevant pairings between
ACAs and corresponding cytokine levels. IL-12 levels correlated weakly with anti-IL-12
autoantibodies (r=0.21, p<0.01), and soluble IL-2R levels, but not IL-2,
negatively correlated with anti-IL-2 autoantibodies
(r=0.23, p<0.01). Plasma IL-2R levels were significantly higher in
patients with GPA compared to the other types of vasculitis (668.3 vs 288.8
ng/ml, p<0.01); among patients with GPA IL-2R levels were 2-fold lower in
patients with anti-IL-2 autoantibodies.

Conclusion:

ACAs occur at differing frequencies across the spectrum of vasculitis.
Interestingly, autoantibodies directed against IL-2 were observed
in a subset of patients with GPA and were negatively correlated with plasma IL-2R
levels, suggesting that these autoantibodies may
play a functional role in disease pathogenesis.
Functional
studies of candidate ACAs in vasculitis are warranted.

Description: Macintosh HD:Users:guptas3:Desktop:2015 ACR Abstract:VCRC:SG Table.tiff


Disclosure: S. Gupta, None; S. K. Patel, None; M. Blake, None; M. G. Gadina, None; W. L. Tsai, None; S. Carette, None; D. Cuthbertson, None; G. S. Hoffman, None; N. A. Khalidi, None; C. L. Koening, None; C. A. Langford, None; C. A. McAlear, None; L. W. Moreland, None; P. A. Monach, None; C. Pagnoux, None; P. Seo, None; U. Specks, None; A. G. Sreih, None; S. R. Ytterberg, None; S. K. Browne, None; S. M. Holland, None; M. J. Kaplan, None; P. A. Merkel, None; P. C. Grayson, None.

To cite this abstract in AMA style:

Gupta S, Patel SK, Blake M, Gadina MG, Tsai WL, Carette S, Cuthbertson D, Hoffman GS, Khalidi NA, Koening CL, Langford CA, McAlear CA, Moreland LW, Monach PA, Pagnoux C, Seo P, Specks U, Sreih AG, Ytterberg SR, Browne SK, Holland SM, Kaplan MJ, Merkel PA, Grayson PC. Anticytokine Autoantibody Profiling in Five Types of Systemic Vasculitis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/anticytokine-autoantibody-profiling-in-five-types-of-systemic-vasculitis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anticytokine-autoantibody-profiling-in-five-types-of-systemic-vasculitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology